PRVB Provention Bio Inc.

11.98
-0.38  -3%
Previous Close 12.36
Open 11.76
Price To Book 6.24
Market Cap 570,707,565
Shares 47,638,361
Volume 660,826
Short Ratio
Av. Daily Volume 635,901
Stock charts supplied by TradingView

NewsSee all news

  1. Provention Bio to Present at Upcoming Conferences

    OLDWICK, N.J., Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that

  2. Provention Bio Highlights Critical New Research Studies on Type One Diabetes

    OLDWICK, N.J., Feb. 6, 2020 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today highlighted several new

  3. Provention Bio Appoints Jason Hoitt as Chief Commercial Officer

    OLDWICK, N.J., Jan. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the

  4. Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA

    OLDWICK, N.J., Dec. 12, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it

  5. Provention Bio Reports Third Quarter 2019 Financial Results

    OLDWICK, N.J., Nov. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b top-line data May 8, 2019 noted primary safety and tolerability endpoint met but efficacy and other secondary endpoints were not met.
PRV-300
Ulcerative Colitis
Phase 3 enrolment to be completed 4Q 2020.
PRV-031 (teplizumab)
Type 1 diabetes
Phase 2a data did not meet primary endpoint - October 22, 2019.
PRV-6527
Crohn's disease
Phase 2b trial to commence 2020.
PRV-015
Celiac disease
Phase 1b data due 1Q 2020.
PRV-3279
Systemic Lupus Erythematosus (SLE) and Lupus nephritis (LN)

Latest News

  1. Provention Bio to Present at Upcoming Conferences

    OLDWICK, N.J., Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that

  2. Provention Bio Highlights Critical New Research Studies on Type One Diabetes

    OLDWICK, N.J., Feb. 6, 2020 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today highlighted several new

  3. Provention Bio Appoints Jason Hoitt as Chief Commercial Officer

    OLDWICK, N.J., Jan. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the

  4. Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA

    OLDWICK, N.J., Dec. 12, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it

  5. Provention Bio Reports Third Quarter 2019 Financial Results

    OLDWICK, N.J., Nov. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial

  6. Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019

    OLDWICK, N.J., Oct. 29, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will

  7. Sean Doherty Joins Provention Bio Board of Directors

    OLDWICK, N.J., Sept. 26, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the

  8. Provention Bio to Present at the 2019 Cantor Global Healthcare Conference

    OLDWICK, N.J., Sept. 25, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that

  9. Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing

    OLDWICK, N.J., Sept. 24, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its

  10. Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock

    OLDWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing

  11. Provention Bio Announces Proposed Public Offering of Common Stock

    OLDWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has

  12. Provention Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    OLDWICK, N.J., Sept. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that